throbber
Tetrahedron Letters,Vol.28,No.l9,pp 2103-2106,1987 oo40-4039/87 $3.00 + .OO Printed in Great Britain Pergamon Journals Ltd.
`
`ENHANCED REACTIVITY OF IMINIUM IONS AS HETERODIENOPHILES
`
`IN LEWIS ACID MEDIATED 4+2 CYCLOADDITION REACTIONS
`
`K.M. RYAN, R.A. REAMER, R.P. VOLANTE AND I. SHINKAI
`
`MERCK SHARP AND DOHME RESEARCH LABORATORIES
`
`DIVISION OF MERCK AND CO., INC.
`
`RAHWAY, NEW JERSEY 07065
`
`Summary: The use of a Lewis acid-proton acid combination was found to be highly
`effective
`for the activation
`of imines
`as heterodienophiles
`in Diels-Alder
`cycloaddition reactions.
`
`The ability of an imine group to function as a heterodienophile
`
`in an apparent
`
`Diels-Alder cycloaddition reaction with a conjugated diene has been shown to possess a
`
`vast potential for the synthesis of a variety of nitrogen containing heterocyc1es.I
`
`However, not all imino compounds are effective dienophiles
`
`in 4+2 cycloaddition
`
`reactions unless exceptionally reactive dienes are employed.
`
`This unreactivity has
`
`been traditionally overcome by activation of the imine function by substitution with
`one or more electron withdrawing groups and/or the use of Lewis acid catalysis. 's3
`
`addition there have been several recent reports concerning the cycloaddition of Mannich
`
`generated iminium ions with conjugated dienes.4
`
`We now wish to report our findings
`
`concerning the enhanced reactivity of iminium ions as heterodienophiles in the presence
`
`of Lewis acids.
`
`7 ~yqygyyi; la OTMS OTMS - - -_ 2103
`
`Page 1
`
`Anacor Exhibit 2020
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`In
`

`

`treated with trifluoroacetic
`
`acid in methylene chloride or chloroform to give the
`
`iminium trifluoroacetate 5. Subsequent addition of 1.0 equivalent of boron trifluoride
`-
`etherate resulted in the quantitative production of the more reactive BF3 mediated
`
`iminium species 5. 'H NMR indicated that the nitrogen of imine 2 was protonated with
`
`the N-H broadened and in rapid exchange at ambient temperature; however, at -20°C a 9.0
`
`Hz vicinal coupling between the imine N-H proton and the methine C-H was observed.
`
`Treatment of 2 with diene 2 led to a quantitative conversion to the desired enol silyl
`
`ether 3*.
`-
`presence of diene 2.
`
`Iminium trifluoroacetate
`
`species 2 did not undergo cycloaddition
`
`in the
`
`The reactive species is believed to be the protonated iminium ion 2 with the boron
`
`trifluoride associated with the trifluoroacetate counterion.
`
`This association should
`
`make iminium ion 6 more naked and hence more reactive.
`-19
`is supported by
`
`F NMR studies showing both an associated
`
`The BF3-counterion association
`
`and non-associated
`
`trifluoroacetate
`
`species
`
`This hypothesis is further supported by the clean,
`
`quantitative conversion of the iminium tetrafluoroborate salt to the enol silyl ether 2
`
`in the absence of a Lewis acid.
`
`HBF4
`
`a
`
`lb
`--
`
`7
`-
`
`Procedure:
`
`dichloromethane
`
`To a stirred solution of imine trimer lb (855 mg, 5.0 mmol) in 15 ml of dry
`-
`at ambient temperature was added trifluoroacetic
`
`acid (385 uL, 5.0
`
`mmol). The solution was stirred for 5 min and boron trifluoride etherate (615 pL, 5.0
`
`nunol) was added. After 5 min the solution was treated with diene 1 (1.32 mL, 7.5 mmol)
`and stirred an additional 30 min at 22-24". The reaction was quenched by washing with
`
`two portions of saturated sodium bicarbonate solution (30 mL each). The organic phase
`
`was separated, dried (Na2S04), and concentrated to give enol silyl ether 3 as a yellow
`-
`oillo.
`_ The oil 3 was dissovled in methanol (20 mL) and stirred over anhydrous sodium
`
`
`partitioned between dichloromethane and water.
`
`carbonate (0.5 g) at 22-24" for 1 hr. The solution was filtered, concentrated, and
`The organic phase was dried (Na2S04)
`10
`and concentrated to give 1.10 g (91%) of ketone 4
`-
`
`as a yellow oil which slowly
`
`crystallized on standing.
`
`Page 2
`
`Anacor Exhibit 2020
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`2104
`739
`.
`

`

`2105
`
`The Lewis acid catalyzed
`
`(BF3-OEt2 or ZnC12) cycloaddition
`
`of 3,4-dihydro-
`
`benzofuro[2,3-clpyridine
`
`(la)5 with 2-(trimethylsilyloxy)-1,3-butadiene
`-
`silyl enol ether 2 was recently reported by Vacca as a general methodology for the
`
`(2) to give the
`
`synthesis of aryl[2,3-alquinolizin-2-ones
`
`(i).6 This finding and our interest in the
`
`quinolizinone system has led us to further investigate this cycloaddition.
`
`We found
`
`lb
`-
`
`A
`--
`
`B
`-
`
`that treatment of benzofuropyridine trimer lb with BF3.0Et2 gave rise to two distinct
`-
`monomeric imine species, 4 (H-C=N, 6=8.9) and i (H-C=N, 6=8.6), of which only species A
`
`was converted to silyl enol ether 3 upon addition of diene 2.
`-
`-
`relative amounts of imine species A and B produced were found to be dependent on the
`-
`purity of both the reagents and the solvents used in the reaction.
`Species i and B -
`were characterized by multinuclear NMR studies and the results are discussed below.
`
`Furthermore, the
`
`Species E was prepared quantitatively from trimer lb by treatment with freshly
`-
`distilled BF3*0Et2 in anhydrous methylene chloride and could be isolated as a solid.
`
`The l3 C NMR for imine 1 shows a 3-bond coupling (J=3.5 Hz) between the sp2 imine carbon
`Furthermore "B and "F NMR show a "F_"B
`
`and the boron fluorines (-C=N-B-F).
`
`splitting indicative of an almost symmetrical tetrahedral boron species.
`
`These facts
`
`imply a strong B-N interaction7.
`
`However, the 'H NMR of reactive species A showed a
`
`broad, rapidly exchanging N-H signal indicating the presence of an adventitious proton
`
`source. An analogous iminimum species was prepared as follows. Trimer lb was first
`-
`
`Page 3
`
`Anacor Exhibit 2020
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`

`

`Acknowledgment:
`
`Helpful discussions with Dr. A.W. Douglas and FT-IR experiments with
`
`Dr. S.M. Riseman are gratefully acknowledged.
`
`References:
`
`1.
`
`Weinreb, S.M.; Staib, R.R. Tetrahedron 1982, 38, 3087; Weinreb, S.M.; Levin,
`
`Heterocycles 1979, 12, 949.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`a.
`
`9.
`
`10.
`
`Kerwin, J.F.; Danishefsky, S. Tetrahedron Lett. 1982, 23, 3739.
`--
`Oppolzer, W. Agnew Chem. Int. Ed. Engl. 1972, 11, 1031; Titov, Y.A. Russ. Chem.
`Rev. 1962, 31, 267.
`--
`Larsen, S.D,; Grieco, P.A. J. Am. Chem. Sot. 1985, 107, 1768.
`
`Monomeric species la exists in equilibrium with the corresponding trimer lb with
`-
`-
`the latter predominating under neutral or basic conditions.
`
`Vacca, J.P. Tetrahedron Lett. 1985, 26, 1277.
`Selected NMR data for B and 6. F-19 and
`"B spectra were obtained in CDC13 on a
`-
`-
`Bruker WM-250 referenced as follows:
`"F, C6F6, 6F=-163.0 ppm; "B, BF3*Et20,
`B: N+BF3,
`6B=-0.45
`6B=0.0 ppm. Negative chemical shifts are to higher field.
`
`ppm, 6F=-155.2, 'JBF=12Hz.
`
`6: CF3C02-BF3, 6B=-0.54 ppm,
`
`6,-76.7 (-CF3),
`
`SF=-149.7 (BF3); excess free CF3C02H, 6F=-76.2.
`
`Other acid/Lewis acid combinations were found to be less effective.
`and FT-IR studies with triethylammonium
`
`"B
`
`"F)
`
`Multinuclear
`
`NMR (13C
`
`trifluoroacetate and boron trifluoride etherate show completely analogous results.
`
`NMR data for 3 and 4. Hydrogen and
`-
`Bruker WM-250 and AM-300 spectrometers.
`
`13C NMR experiments were run in CDC13 on
`
`Assignments were made using homo- and
`
`hetero nuclear 2-D experiments (COSY-45, HETCOR).
`
`were used to assign the quaternary carbons in 4.
`-
`primarily of overlapped multiplets the more informative 13C data are reported.
`
`Fully 'H coupled 13C spectra
`1
`H spectra consist
`
`Since
`
`13C NMR 3: (CDC13, 6C=77.0ppm) 0.33(OSi(CH3)3), 21.0(C7), 34.2(C1), 51.2(C6), 52.9
`
`(C,), 55.9(C12b), 101.4(C3), lll.0(C7,), 111.2(Cll), 118.8(Ca), 122.4(Cg), 123.4
`
`(Cl,), 128.1(C7,), 14B.1(C2), 153.3(C12a), 154.9(Clla).
`
`4: (CDC13, 6c=77.0 ppm)
`
`20.9(C7), 41.2(C3), 43.7(C1), 51.0(C6), 53.6(C4), 58.1 (C12b), lll.0(C7b, Cl&
`
`118.6(Ca),
`
`122.3(Cg),
`
`123.5(Clo),
`
`127.5(C7a),
`
`151.5
`
`(C12a),
`
`154.4(Clla),
`
`206.7(C2).
`
`Page 4
`
`Anacor Exhibit 2020
`Flatwing Pharmaceuticals, Inc. v. Anacor Pharmaceuticals, Inc
`IPR2018-00170
`
`2106
`J.I.
`-
`,
`,
`(Received in USA 26 February 1987)
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket